Antilymphoblast globulin in renal transplant patients. No allergic reactions

The incidence and type of allergic reactions to antilymphoblast globulin (ALG) and their relationship to skin testing, histamine release, and serum levels of ALG and anti-ALG antibodies were studied prospectively in 50 patients receiving high-dose ALG therapy intravenously for the first two weeks after renal transplantation. No clinically apparent allergic reactions occurred in the patients studied.